
    
      In this open, multicentre, dose escalation study, successive cohorts of 3 patients suffering
      from advanced or metastatic melanoma will be electrotransferred increasing doses of Plasmid
      AMEP into cutaneous melanoma lesions in 2 divided doses at one week interval.
    
  